- Home
- DNLI vs DEI Comparison
DNLI vs DEI Comparison
Compare DNLI & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- DEI
- Stock Information
- Founded
- DNLI 2013
- DEI 1971
- Country
- DNLI United States
- DEI United States
- Employees
- DNLI N/A
- DEI N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- DEI Real Estate Investment Trusts
- Sector
- DNLI Health Care
- DEI Real Estate
- Exchange
- DNLI Nasdaq
- DEI Nasdaq
- Market Cap
- DNLI 2.1B
- DEI 2.5B
- IPO Year
- DNLI 2017
- DEI 2006
- Fundamental
- Price
- DNLI $13.92
- DEI $15.44
- Analyst Decision
- DNLI Strong Buy
- DEI Buy
- Analyst Count
- DNLI 15
- DEI 9
- Target Price
- DNLI $33.85
- DEI $18.13
- AVG Volume (30 Days)
- DNLI 1.7M
- DEI 1.7M
- Earning Date
- DNLI 07-31-2025
- DEI 08-05-2025
- Dividend Yield
- DNLI N/A
- DEI 4.87%
- EPS Growth
- DNLI N/A
- DEI N/A
- EPS
- DNLI N/A
- DEI 0.32
- Revenue
- DNLI N/A
- DEI $995,663,000.00
- Revenue This Year
- DNLI N/A
- DEI $1.10
- Revenue Next Year
- DNLI $335.74
- DEI $2.30
- P/E Ratio
- DNLI N/A
- DEI $49.31
- Revenue Growth
- DNLI N/A
- DEI 1.93
- 52 Week Low
- DNLI $10.57
- DEI $12.39
- 52 Week High
- DNLI $33.33
- DEI $20.50
- Technical
- Relative Strength Index (RSI)
- DNLI 48.38
- DEI 56.46
- Support Level
- DNLI $13.83
- DEI $14.75
- Resistance Level
- DNLI $14.66
- DEI $15.35
- Average True Range (ATR)
- DNLI 0.63
- DEI 0.37
- MACD
- DNLI -0.03
- DEI 0.02
- Stochastic Oscillator
- DNLI 31.58
- DEI 71.23
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.